These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36625202)

  • 1. Ectopic CH60 mediates HAPLN1-induced cell survival signaling in multiple myeloma.
    De Bakshi D; Chen YC; Wuerzberger-Davis SM; Ma M; Waters BJ; Li L; Suzuki A; Miyamoto S
    Life Sci Alliance; 2023 Mar; 6(3):. PubMed ID: 36625202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma.
    Huynh M; Pak C; Markovina S; Callander NS; Chng KS; Wuerzberger-Davis SM; Bakshi DD; Kink JA; Hematti P; Hope C; Asimakopoulos F; Rui L; Miyamoto S
    J Biol Chem; 2018 Feb; 293(7):2452-2465. PubMed ID: 29279332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Hyaluronan and Proteoglycan Link Protein 1 Matrikine: Role of Matrix Metalloproteinase 2 in Multiple Myeloma NF-κB Activation and Drug Resistance.
    Mark C; Warrick J; Callander NS; Hematti P; Miyamoto S
    Mol Cancer Res; 2022 Sep; 20(9):1456-1466. PubMed ID: 35604822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HAPLN1 matrikine: a bone marrow homing factor linked to poor outcomes in patients with MM.
    Chang HY; Huynh M; Roopra A; Callander NS; Miyamoto S
    Blood Adv; 2023 Nov; 7(22):6859-6872. PubMed ID: 37647592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs.
    Huynh M; Chang HY; Lisiero DN; Ong IM; Kashyap T; Callander NS; Miyamoto S
    PLoS One; 2022; 17(12):e0274704. PubMed ID: 36480501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-canonical NFκB mutations reinforce pro-survival TNF response in multiple myeloma through an autoregulatory RelB:p50 NFκB pathway.
    Roy P; Mukherjee T; Chatterjee B; Vijayaragavan B; Banoth B; Basak S
    Oncogene; 2017 Mar; 36(10):1417-1429. PubMed ID: 27641334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Andrographolide inhibits multiple myeloma cells by inhibiting the TLR4/NF-κB signaling pathway.
    Gao H; Wang J
    Mol Med Rep; 2016 Feb; 13(2):1827-32. PubMed ID: 26707811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importin β1 mediates nuclear factor-κB signal transduction into the nuclei of myeloma cells and affects their proliferation and apoptosis.
    Yan W; Li R; He J; Du J; Hou J
    Cell Signal; 2015 Apr; 27(4):851-9. PubMed ID: 25643631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
    Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
    Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and function of toll-like receptors in multiple myeloma patients: toll-like receptor ligands promote multiple myeloma cell growth and survival via activation of nuclear factor-kappaB.
    Xu Y; Zhao Y; Huang H; Chen G; Wu X; Wang Y; Chang W; Zhu Z; Feng Y; Wu D
    Br J Haematol; 2010 Sep; 150(5):543-53. PubMed ID: 20629663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Celastrol inhibits lipopolysaccharide-induced angiogenesis by suppressing TLR4-triggered nuclear factor-kappa B activation.
    Ni H; Zhao W; Kong X; Li H; Ouyang J
    Acta Haematol; 2014; 131(2):102-11. PubMed ID: 24157922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of LEF1 Impairs Myeloma Cell Growth Through Modulating CYLD/NF-κB Signaling.
    Zhang G; Miao F; Liu K; Wu J; Xu J
    Technol Cancer Res Treat; 2021; 20():15330338211034270. PubMed ID: 34269120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells.
    Bhardwaj A; Sethi G; Vadhan-Raj S; Bueso-Ramos C; Takada Y; Gaur U; Nair AS; Shishodia S; Aggarwal BB
    Blood; 2007 Mar; 109(6):2293-302. PubMed ID: 17164350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the cross-talk between the hedgehog and NF-κB signaling pathways in multiple myeloma.
    Cai K; Na W; Guo M; Xu R; Wang X; Qin Y; Wu Y; Jiang J; Huang H
    Leuk Lymphoma; 2019 Mar; 60(3):772-781. PubMed ID: 30644322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop.
    Bagratuni T; Sklirou AD; Kastritis E; Liacos CI; Spilioti C; Eleutherakis-Papaiakovou E; Kanellias N; Gavriatopoulou M; Terpos E; Trougakos IP; Dimopoulos MA
    Sci Rep; 2019 Mar; 9(1):3245. PubMed ID: 30824741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis.
    Bharti AC; Shishodia S; Reuben JM; Weber D; Alexanian R; Raj-Vadhan S; Estrov Z; Talpaz M; Aggarwal BB
    Blood; 2004 Apr; 103(8):3175-84. PubMed ID: 15070700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platycodin D inhibits proliferation, migration and induces chemosensitization through inactivation of the NF-κB and JAK2/STAT3 pathways in multiple myeloma cells.
    Wu D; Zhang W; Chen Y; Ma H; Wang M
    Clin Exp Pharmacol Physiol; 2019 Dec; 46(12):1194-1200. PubMed ID: 31347196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of NF-κB DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation.
    Bariana M; Cassella E; Rateshwar J; Ouk S; Liou HC; Heller C; Colorado I; Feinman R; Makhdoom A; Siegel DS; Heller G; Tuckett A; Mondello P; Zakrzewski JL
    Mol Cancer Ther; 2022 Dec; 21(12):1798-1809. PubMed ID: 36190955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.
    Murray MY; Zaitseva L; Auger MJ; Craig JI; MacEwan DJ; Rushworth SA; Bowles KM
    Cell Cycle; 2015; 14(14):2367-75. PubMed ID: 25565020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.